Sotera Health
0
Funds holding %
of 7,398 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
225% more call options, than puts
Call options by funds: $1.16M | Put options by funds: $356K
54% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 57
30% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 30
4% more funds holding
Funds holding: 207 [Q3] → 215 (+8) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 11 [Q3] → 11 (+0) [Q4]
0.22% less ownership
Funds ownership: 93.48% [Q3] → 93.27% (-0.22%) [Q4]
18% less capital invested
Capital invested by funds: $4.42B [Q3] → $3.61B (-$803M) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$16
44%
upside
Avg. target
$16
44%
upside
High target
$16
44%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Barclays Luke Sergott 22% 1-year accuracy 11 / 51 met price target | 44%upside $16 | Overweight Maintained | 28 Feb 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
4 weeks ago
Nelson Labs Launches Innovative Rapid Sterility Testing to Significantly Expedite Product Sterility Results
Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application Rapid Sterility Testing yields product sterility test results in as little as 6 days and can be used for broadscale medical device and pharmaceutical product application

Neutral
Seeking Alpha
1 month ago
Sotera Health Company (SHC) Q4 2024 Earnings Call Transcript
Sotera Health Company (NASDAQ:SHC ) Q4 2024 Earnings Conference Call February 27, 2025 9:00 AM ET Company Participants Jason Peterson – Vice President of Investor Relations and Treasurer Michael Petras – Chairman and Chief Executive Officer Jon Lyons – Chief Financial Officer Conference Call Participants Patrick Donnelly - Citi Sean Dodge – RBC Capital Markets Luke Sergott – Barclays Casey Woodring – J.P. Morgan Brett Fishbin – KeyBanc Dave Windley – Jefferies Michael Polark – Wolfe Research Operator Good morning, and welcome to the Sotera Health Fourth Quarter and Full Year 2024 Conference Call.

Positive
Zacks Investment Research
1 month ago
Compared to Estimates, Sotera Health (SHC) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Sotera Health (SHC) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Positive
Zacks Investment Research
1 month ago
Sotera Health Company (SHC) Meets Q4 Earnings Estimates
Sotera Health Company (SHC) came out with quarterly earnings of $0.21 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.26 per share a year ago.

Neutral
GlobeNewsWire
1 month ago
Sotera Health Reports Fourth-Quarter and Full-Year 2024 Results; Provides 2025 Outlook
CLEVELAND, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced financial results for the fourth-quarter and full-year 2024 and its initial 2025 outlook.

Neutral
Zacks Investment Research
1 month ago
Insights Into Sotera Health (SHC) Q4: Wall Street Projections for Key Metrics
Evaluate the expected performance of Sotera Health (SHC) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Neutral
GlobeNewsWire
1 month ago
Sotera Health Announces Fourth-Quarter and Full-Year 2024 Earnings Release Date
CLEVELAND, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, today announced its plans to release its financial results for the fourth-quarter and full-year ended December 31, 2024 before the market opens on Thursday, February 27, 2025. Following the release, management will hold a conference call at 9:00 a.m. Eastern Time to discuss the Company's operating highlights and financial results.

Neutral
GlobeNewsWire
2 months ago
Sotera Health Chairman and CEO Presents at 43rd Annual J.P. Morgan Healthcare Conference
CLEVELAND, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is presenting today at the 43rd Annual J.P. Morgan Healthcare Conference. During the presentation, Chairman and CEO Michael B. Petras, Jr. will be providing an update on Sotera Health's business.

Neutral
GlobeNewsWire
2 months ago
Sotera Health to Present at the 43rd Annual J.P. Morgan Healthcare Conference
CLEVELAND, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (“Sotera Health” or the “Company”) (NASDAQ: SHC), a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry, today announced that Chairman and CEO Michael B. Petras, Jr. will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 11:15 a.m. Eastern Time. Mr. Petras, Jon Lyons, Senior Vice President and CFO, and Jason Peterson, Vice President, Investor Relations and Treasurer, will participate in meetings with investors during the conference.

Neutral
GlobeNewsWire
2 months ago
Sotera Health Company Appoints Vincent K. Petrella as Lead Independent Director
CLEVELAND, Ohio, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sotera Health Company (Nasdaq: SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, is pleased to announce today the appointment of Vincent K. Petrella as Lead Independent Director, effective January 2, 2025.

Charts implemented using Lightweight Charts™